Creative Biolabs

/by

Recombinant antibody technology defines the future of biopharmaceutical development, Creative Biolabs says A prominent CRO, Creative Biolabs, has announced their intention to drive the biopharmaceuticals industry forward and has highlighted the role of recombinant antibody engineering in research and drug development efforts. Creative Biolabs is transforming the scope of biopharmaceutical development with its cutting-edge recombinant antibody products and custom antibody discovery solutions. Their specialized products, like antibodies, antibody-like scaffold proteins, and antibody-cytokine fusion proteins, apply to both pharmaceutical discovery projects and disease research endeavors. “Our flagship product, recombinant antibodies, offers high-affinity solutions for a wide variety of applications, from therapeutic development to diagnostic assays, almost covering any prevalent research target. Our robust recombinant DNA technology platform for antibody production and versatile expression systems ensure the highest purity and specificity in the yielding antibodies, enabling researchers to achieve accurate and reliable results.” According to a scientist at Creative Biolabs. Creative Biolabs also supplies the most comprehensive list of antibody-like scaffold proteins, including over 30 different types, such as 10-FnIII, Min-23, ubiquitin, Kunitz domains, PDZ domain, and Z-domain of protein A, which possess the ability to simultaneously interact and/or bind with multiple other proteins and organize partner proteins into a framework to facilitate their concerted interactions and functions. Those scaffold proteins provide a stable framework for the design of novel biologics and can be customized to meet specific research needs. Moreover, Creative Biolabs excels in the development of functional immunocytokines, especially antibody-cytokine fusion proteins (ACFP), a groundbreaking approach to enhancing the efficacy and specificity of immunotherapeutic agents. By combining the targeting capabilities of antibodies with the immune-modulating properties of cytokines, the fusion proteins hold promise for the treatment of cancer, autoimmune diseases, and other conditions. “Our fusion proteins have distinctive advantages, including a rather low immunogenicity, a high affinity of subnanomolars, and outstanding solubility in aqueous solutions.” The scientist introduced. “At Creative Biolabs, we are dedicated to pushing the boundaries of biopharmaceutical development through our innovative antibody solutions. Our commitment to excellence and scientific advancement drives us to deliver premium products and services that empower our clients to make a difference in the field of biotechnology. Our antibody and protein products that I’ve just highlighted are just the tip of the iceberg.” Website: https://www.creativebiolabs.net/ AboutUtilizing advanced techniques like recombinant DNA, Creative Biolabs is able to rapidly customize antibodies for various applications, covering both diagnostics and therapeutics. A group of scientists will attend several 2024 industry conferences to share views with global researchers about frontier discoveries and establish partnerships. Their agenda includes BIO International 2024, World Bispecific Summit, Exosome-Based Therapeutic Summit, and World ADC San Diego.  

Prof. Joshua Yindenaba Abor, PhD, FCCA, FGA

/by

Joshua Yindenaba Abor is a financial economist, qualified accountant. Professor of Finance and former Dean, University of Ghana Business School. He is an Adjunct Professor of Development Finance at the University of Stellenbosch Business School as well as an Adjunct Professor of Finance at SDD-University of Economic Research Consortium. He is an External Fellow at the Centre for Global Finance, SOAS University of London and a Fellow of the Ghana Academy of Arts and Sciences. He has held Visiting Scholar positions at the International Monetary Fund (IMF), Washington DC, US. He also serves on the boards of some companies, including SAS Finance Group, and chairs the SIC Life Company Ltd board. (The Largest life insurance company in Ghana) and is currently a member of the Bank of Ghana Monetary Policy Committee.

Dr. Elikplimi K. Agbloyor

/by

Dr. Elikplimi K. Agbloyor is a Consultant at the Corporate Support Group Ltd and a Senior Lecturer at the University of Ghana Business School. He is also a research fellow in the Faculty of Economic and Management Sciences, University of Stellenbosch Business School, South Africa. He spent a year’s Sabbatical in Australia and was part of the Teaching Team for International Finance at the Monash Business School (a G8 University in Australia and ranked in the Top 100 globally). He is a financial economist, chartered accountant, and risk management, expert. He has several years of teaching, research, and consulting experience. Elikplimi has also consulted for organizations including the International Finance Corporation (IFC), Ghana Oil and Gas for Inclusive Growth (GOGIG), and the National Banking College. He is a researcher with the African Economic and Research Consortium (AERC). Elikplimi has facilitated training programs in retirement planning for a number of institutions including SSNIT, WAEC, and the Ghana Ports and Harbour Authority (GPHA). Elikplimi has experience in managing investment portfolios and has traded CFDs, commodities, derivatives, ETFs, and stocks.